Guangdong Hybribio Biotech (300639.SZ) subsidiary Chloroquine Phosphate Gel approved to conduct clinical trials.

Guangdong Hybribio Biotech (300639.SZ) announced recently that its wholly-owned subsidiary, Guangzhou Guangdong Hybribio Biotech Technology Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the "Chloroquine Phosphate Gel". Chloroquine Phosphate Gel is a treatment drug for HPV virus infection. This approval is for clinical trials of Chloroquine Phosphate Gel for the treatment of high-risk HPV virus infection. It is noted that there are currently no similar products approved for marketing domestically or internationally.